BC Week In Review | Jun 29, 2018
Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...
BC Extra | Jun 28, 2018
Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...
BC Week In Review | Jan 11, 2016
Company News

Celleron, Nuance Biotech deal

Celleron granted Nuance an exclusive option to develop and commercialize CXD101 and CXD201 in South Africa, Taiwan and China, including Macau and Hong Kong. CXD101 is a histone deacetylase (HDAC) inhibitor, and CDX201 is oral...
BC Extra | Jan 8, 2016
Company News

Nuance gains territorial rights to Celleron candidates

Celleron Therapeutics Ltd. (Abingdon, U.K.) granted Nuance Biotech Inc. (Shanghai, China) an exclusive option for development and commercialization rights to oncology candidates CXD101 and CXD201 in Greater China and South Africa. CXD101 is an oral...
Items per page:
1 - 4 of 4